Quantcast
Channel: BioTuesdays » UPDRS III
Viewing all articles
Browse latest Browse all 2

Amarantus eltoprazine PD data published

0
0

Amarantus BioSciences Holdings (OTCQB:AMBS) announced the publication of results of a Phase 2a study of eltoprazine in Parkinson’s disease levodopa-induced dyskinesias (PD-LID).

BrainjThe paper titled, “Eltoprazine Counteracts L-DOPA-induced Dyskinesias in Parkinson’s disease: A Dose-Finding Study,” has been published in Oxford Journals (Oxford University Press) online and will appear shortly in a future print edition of BRAIN – A Journal of Neurology.

The double-blind, randomized, placebo-controlled clinical study was led by Dr. Per Svenningsson, Centre for Molecular Medicine, Karolinska Institutet; Prof. Anders Bjorklund, faculty of medicine at Lund University; and Dr. Hakan Widner, faculty of medicine at Lund University. The study was partially supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research.

Data from the study demonstrated that eltoprazine significantly reduced peak dose dyskinesia at both the 5 mg and 7.5 mg doses using the Combined Dyskinesia Rating Scale. The 5 mg dose also showed a significant anti-dyskinetic effect on other measures of dyskinesia, including the Rush dyskinesia rating scale.

“Eltoprazine’s anti-dyskinetic effect is promising, especially given the reduction in dyskinesia following a levodopa challenge at one and a half times greater than the regular levodopa dose,” said Dr. Charlotte Keywood, CMO of Amarantus.

Levodopa treatment is the current standard of care for patients to manage PD motor symptoms, despite the occurrence of dyskinesia with long-term use. “Thus, we were very pleased to see that normal motor responses to levodopa, measured by UPDRS III, remained unchanged in all patients treated with eltoprazine,” she added.

Amarantus expects to file and IND with the FDA and commence a Phase 2b study of eltoprazine in PD-LID subjects in the first quarter of 2015.


Viewing all articles
Browse latest Browse all 2

Latest Images

Trending Articles





Latest Images